Orion Corporation

Aranda Pharma Ltd

Medeia Therapeutics Ltd

Jari Ratilainen

Arja Karjalainen

Paavo Huhtala

Arto J Karjalainen

Olli Törmäkangas

Antti Haapalinna

Milla Koistinaho

Anu Muona

Gerd Wohlfahrt

Raimo E Virtanen

David Din Belle

Arto Tolvanen

Jukka Sallinen

Jyrki Lehtim&auml;ki

Anu Moilanen

Gundars Goldsteins

Reija Jokela

Pekka Kallio

The present invention relates to arylthiazine compounds, metabolites, N-oxides, amides, esters, pharmaceutically acceptable salts, hydrates and solvates thereof and their use as cytoprotectants in the treatment or prophylaxis of diseases or states, either acute or chronic, involving aberrant cellular lipid peroxidation in the central nervous system or in the periphery of the body. The present invention also relates to a method for their preparation and to pharmaceutical composition comprising as an active ingredient one or more of the aforementioned compounds.

Use of condensed benzo[B]thiazine derivatives as cytoprotectants

The invention relates to novel heteroarylamide derivatives having formula (I) and N-oxides, stereoisomers and pharmaceutically acceptable salts thereof, where R, R, R1 1, R', R&#x2033;, z and X are as defined in the claims. The arylamide derivatives of formula (I) have antiandrogenic properties. The invention also relates to compounds of formula (I) for use as a medicament and to pharmaceutical compositions comprising them and to their preparation. 

Heteroarylamide derivatives having antiandrogenic properties

The invention relates to novel arylamide derivatives having formula (I) and stereoisomers and pharmaceutically acceptable salts thereof, where R1-R11, R', R&#x2033;, z and X are as defined in the claims. The arylamide derivatives of formula (I) have antiandrogenic properties. The invention also relates to compounds of formula (I) for use as a medicament and to pharmaceutical compositions comprising them and to their preparation. 

Arylamide derivatives having antiandrogenic properties

A compound of formula (I), an isomer, metabolite, or a pharmaceutically acceptable salt or ester thereof is disclosed. Compounds of the invention possess utility as a tissue-selective androgen receptor modulators (SARM) and are useful in hormonal therapy, e.g. in the treatment or prevention of hypogonadism, muscle wasting, osteoporosis, benign prostate hyperplasia, obesity associated with a metabolic syndrome, male and female sexual dysfunction and reduced libido, and androgen decline in aging male or female.

Selective androgen receptor modulators

Polycyclic compounds as potent alpha2-adrenoceptor antagonists

Compounds of formula (I) wherein R1 to R4, X and A are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds of formula (I) possess utility as tissue-selective androgen receptor modulators (SARM) and are useful in hormonal therapy, e.g., in the treatment or prevention of male hypogonadism and age-related conditions such as andropause.

Propionamide derivatives useful as androgen receptor modulators

Polycyclic indanylimidazoles with alpha2 adrenergic activity

Growing community of inventors

Kulho, Finland

Jari Ratilainen